Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma
We compared the oncological outcomes of papillary renal cell carcinoma (pRCC) with clear cell renal cell carcinoma (ccRCC) after partial nephrectomy (PN) in patients with pathologic T1a RCC.
After excluding patients with synchronous multiple renal tumors, familial RCC, and pathologic stage T1b or above, 759 patients with ccRCC and 84 patients with pRCC were included. We assessed the impact of histologic subtypes on oncologic outcomes after PN in patients with pathologic T1a RCC (median follow-up duration, 67 months).
There was no difference in patient and tumor characteristics between the 2 groups, except Fuhrman grade (p = 0.006). Kaplan–Meier analysis identified 5-year recurrence-free survival of 98.7 and 95.6% in patients with ccRCC and pRCC, respectively. However, 10-year recurrence-free survival in patients with ccRCC and pRCC was 96.1 and 73.0%, respectively (p < 0.001). Recurrence ≥5 years post surgery was more common in patients with pRCC compared with those with ccRCC (0.3 vs. 4.8%; p < 0.001). In multivariate analysis, pRCC [hazard ratio (HR) 5.309; p = 0.001] was a significant risk factor for recurrence after PN in patients with pathologic T1a RCC, in addition to larger tumor size (HR 1.861; p = 0.038) and Fuhrman grade ≥3 (HR 5.176; p = 0.003).
In patients with pathologic T1a RCC, recurrence after PN occurred more commonly in pRCC compared with ccRCC. As over half of the recurrence cases in patients with pRCC occurred ≥5 years post surgery, a longer follow-up time is required, even for those with pathologic stage T1a disease.
KeywordsCarcinoma, renal cell Neoplasms by histologic type Recurrence
Renal cell carcinoma
Papillary renal cell carcinoma
Clear cell renal cell carcinoma
There is no financial disclosure from any authors.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Research involving human participants and/or animals
This article does not contain any studies with human participants performed by any of the authors.
For this type of study, formal consent is not required.
- Ha YS et al (2016) Clinical significance of subclassification of papillary renal cell carcinoma: comparison of clinicopathologic parameters and oncologic outcomes between papillary histologic subtypes 1 and 2 using the Korean renal cell carcinoma database. Clin Genitourin Cancer 45(2):e181–e186. doi: 10.1016/j.clgc.2016.07.020 CrossRefPubMedGoogle Scholar
- Thompson RH, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED, Cheville JC, Blute ML (2008) Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol 179:468–471. doi: 10.1016/j.juro.2007.09.077 (discussion 472–463) CrossRefPubMedGoogle Scholar
- Yamamoto A, Tamada T, Ito K, Sone T, Kanki A, Tanimoto D, Noda Y (2017) Differentiation of subtypes of renal cell carcinoma: dynamic contrast-enhanced magnetic resonance imaging versus diffusion-weighted magnetic resonance imaging. Clin Imaging 41:53–58. doi: 10.1016/j.clinimag.2016.10.001 CrossRefGoogle Scholar
- Young JR, Coy H, Kim HJ, Douek M, Lo P, Pantuck AJ, Raman SS (2017) Performance of relative enhancement on multiphasic MRI for the differentiation of clear cell renal cell carcinoma (RCC) from papillary and chromophobe RCC subtypes and oncocytoma. AJR Am J Roentgenol 208(4):812–819. doi: 10.2214/ajr.16.17152 CrossRefPubMedGoogle Scholar